STAR and polycystic ovary syndrome: However, administration of fractalkine blocked this reduction in progesterone (1.218 ± 0.169 versus 1.284 ± 0.110 for PCOS with fractalkine versus Ctl with fractalkine, respectively P > 0.05; n = 8; Fig. 3A) and STAR expressions (1.306 ± 0.253 versus 1.454 ± 0.131 for PCOS with fractalkine versus Ctl with fractalkine, respectively; P > 0.05; n = 7; Fig. 3B) in PCOS groups.